Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High – Time to Buy?

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) reached a new 52-week high during trading on Monday . The stock traded as high as $15.20 and last traded at $15.11, with a volume of 172818 shares changing hands. The stock had previously closed at $14.66.

Analyst Upgrades and Downgrades

TBPH has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. B. Riley initiated coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $23.00.

Theravance Biopharma Price Performance

The stock has a market cap of $763.93 million, a price-to-earnings ratio of 63.08 and a beta of -0.03. The company’s 50 day moving average is $14.10 and its 200 day moving average is $11.89.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Bank of New York Mellon Corp raised its position in shares of Theravance Biopharma by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock worth $1,049,000 after purchasing an additional 1,720 shares during the period. Tabor Asset Management LP bought a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $135,000. Brookwood Investment Group LLC acquired a new position in shares of Theravance Biopharma during the first quarter worth approximately $188,000. GSA Capital Partners LLP grew its holdings in Theravance Biopharma by 11.9% in the 1st quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company’s stock worth $1,628,000 after buying an additional 19,363 shares in the last quarter. Finally, XTX Topco Ltd increased its position in Theravance Biopharma by 20.8% in the 1st quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,403 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.